Figure 3.

Higher CHF risk in patients with greater than median body weight change. Kaplan–Meier curves showing the cumulative incidence of CHF by avosentan and placebo treatment arms and greater or smaller than median body weight change (upper panel) or greater or smaller than median hemoglobin change (lower panel). In both panels, CHF risk is higher in the avosentan treatment arm. Among avosentan-allocated patients, however, CHF risk compared with placebo is only higher in those with above median body weight change and not in those with below median body weight change (P for interaction=0.04). In contrast, avosentan-induced CHF risk is higher in patients with either above or below median hemoglobin change (P for interaction=0.64).